MDGL Madrigal Pharmaceuticals Inc

$MDGL 55.4 mil net income. 1.1 billion revenue YTD. Probably will do 1.6 bil for 2026. Awesome.

$MDGL $431M net sales for Rezdiffra, doubling of patients on therapy YoY Interesting strategy of offering Rezdiffra alongside GLP-1 to endocrinologists vs pitting against each other (not a zero sum game)

$MDGL I’m shocked big Pharma hasn’t inquired yet. These revs are accelerating quick. With much more room to grow

$MDGL first profitable quarter, 431.3 million dollars of Rezdiffra sales in Q3, and the 10-Q shows what built up underneath it. Gross to net reserves doubled to 208.3 million dollars at Sep 30 from 99.3 million dollars at year end, and nine month operating cash flow was still negative 23.6 million dollars. Inventory was 122.6 million dollars, but 113.3 million dollars of it was work in process against just 9.3 million dollars of finished goods, after a 10.4 million dollar write down in Q2 for product that did not meet quality specifications.

$MDGL Criminal how this stock gets manipulated. blowout earnings and profitability. Price goes down

$MDGL ✅ In today’s candle, you can see all the interest, the frenzy, and the passion for the days to come—patience, folks; we’re in the right place.

$MDGL This was the mission of these scoundrels: TO FILL THE GAP; now, let us work to arrive at the truth.

$MDGL What exactly is the short thesis here?????? They are making too much $ and growing too fast??????😂😂😂😂

trending for a reason imo $MDGL just put up its first profitable quarter, 431.3 million in Rezdiffra sales up 50 percent year over year, 55,850 patients on drug, and the stock is up about 6.6 percent near 459 off a 431 close. it's funny how sellers spent a month fading a launch that just crossed 1.1 billion year to date

$MDGL To sum this up the sellers here are really missing the bigger picture. I bet BP will not. $750-$1200 Mark it!

$MDGL 🚨🚨🚨🚨🚨 Madrigal Pharmaceuticals, Inc. reported third-quarter 2026 net revenues of $431.3 million, up 50% from $287.3 million in the comparable prior-year period; Rezdiffra net sales were also $431.3 million. Net income was $55.4 million, versus a $114.2 million net loss a year earlier, marking the company’s first quarter of profitability. Operating expenses were $375.3 million, compared with $401.2 million in the prior-year period; R&D expenses were $71.8 million versus $174.0 million, and SG&A expenses were $265.7 million versus $209.1 million. Cash, cash equivalents, restricted cash and marketable securities totaled $961.8 million as of September 30, 2026, compared with $988.6 million as of December 31, 2025. More than 55,850 patients were on Rezdiffra as of September 30, 2026. The U.S. F2-F3 MASH market had more than 530,000 addressable patients through June 30, 2026; Madrigal said it was on track for more than 30% growth by year-end 2026. Madrigal plans MAESTRO-CSPH, a second Phase 3 outcomes trial expected to enroll more than 2,000 F4c patients, with a population significantly enriched for clinically significant portal hypertension. Trial initiation is expected in the first half of 2027, subject to regulatory discussions; data from MAESTRO-NASH OUTCOMES are expected in late 2027.

$MDGL Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates

$MDGL ✅ After a long absence from Madrigal, I’m back. This pullback offers an excellent entry point, with the aim of capitalizing on the upcoming quarterly results—it’s a fantastic company, with solid revenue growth and no competitors at the moment. GO MADRIGAL!

$MDGL the street will be overly critical on the EPS-script numbers and spend (SG&A), I hope they have it under control and toned down

$MDGL Most of the times this kind if manipulation (without any news) is seen before BO!! Hope this is the case for MDGL too, BO soon?

$MDGL hopefully we can do around 700,000 shares today, which should drive the price higher.

$MDGL this is a one of a kind: The second will evaluate MGL286, our oral GLP-1 agonist, with resmetirom, following completion of the ongoing Phase study. Our goal remains to dial in the right amount of weight loss to enhance resmetirom's anti-fibrotic effect while preserving tolerability. The third will evaluate MGL0795, our siRNA targeting PNPLA3, with resmetirom. This is our genetically targeted approach for patients homozygous for a PNPLA3 disease-accelerating mutation. Our earlier-stage pipeline is advancing as well, with six siRNA programs and three exploratory assets. Our approach to our pipeline remains disciplined and focused on combination programs with the potential to deliver the greatest benefit to patients living with MASH.

$MDGL gotta be patient : Third, MAESTRO-CSPH enhances our opportunity to build Rezdiffra-specific biomarker evidence. We plan to collect a rich set of biomarkers and non-invasive data in MAESTRO-CSPH, as we've done in MAESTRO-NASH Outcomes. Using the data from MAESTRO-NASH Outcomes, we can identify measures that are most closely associated with treatment benefit and potentially validate those findings in MAESTRO-CSPH. And fourth is scale. Across MAESTRO-NASH Outcomes and MAESTRO-CSPH, we expect our F4C outcomes-based clinical program to include approximately 3,000 patients, which will give us the greatest insight into this population and further strengthen our competitive advantage. Overall, we believe MAESTRO-CSPH will be the defining F4C study in this space. We plan to finalize the study protocol following our discussions with FDA and initiate the study in the first half of next year, with results expected in the early 2030s.

$MDGL any predictions for Tuesday? Running out of patience for this one. Did trim some along the way. With my luck it will run as soon as I exit.

$MDGL Now Bill is replacing "mega blockbuster" said this 10 times to now "Holygrail" of pharma.